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Background
The cryopyrin-associated periodic syndrome (CAPS) is a
rare but treatable inherited autoinflammatory condition
including familial cold autoinflammatory syndrome
(FCAS), Muckle-Wells syndrome (MWS) and chronic
infantile neurologic cutaneous articular syndrome
(CINCA). Without treatment, some patients develop AA
amyloidosis with consequent renal failure and death.
Objective
To describe the main features of CAPS-associated AA
amyloidosis and the efficacy of interleukin-1 inhibitors
in this complication.
Methods
We retrospectively analysed all current French CAPS-
associated amyloidosis cases through the French net-
work for rare diseases, and performed a systematic lit-
erature review of such cases published since 1950.
Results
Fourteen French patients were identified (6 women/8 men)
including MWS (n=9), FCAS (n=3), CINCA (n=2) and hav-
ing received interleukin-1 inhibitors in 7 cases. Mean age at
the diagnosis of amyloidosis was 22.6 years and five
(35.7 %) patients died. We found 53 patients in the litera-
ture, with a sex ratio of 1. They included MWS (n=34),
FCAS/MWS (n=12) and FCAS (n=7). Among 67 patients
(French and literature), the median age at amyloidosis
diagnosis was 30 years, ranging from 12 to 61 years. The
NLRP3 gene was sequenced in 30 patients (45.5%), and the
distribution of amino acids changes was as follows: R262W
(n=16), T348M (n=5), A439V (n=4), D303N (n=3), T436N
(n=2) and L353P (n=1). 23 patients had died (35%), but
none of them had received interleukin-1 inhibitors. Since
2002, 24/67 (36%) patients with CAPS-associated amyloido-
sis have received interleukin-1 inhibitors, with at least a
decrease of proteinuria and creatininemia in 9 of them
(37.5%)
Discussion
AA amyloidosis can occur in all CAPS phenotypes, even
if it was more frequent in MWS. This study underlines
that even if FCAS is considered as a milder clinical phe-
notype compared to MWS or CINCA, it can also lead to
amyloidosis. Thus, if FCAS patients display continuous
subclinical inflammation, they should receive Interleu-
kin-1 inhibitors as well, in order to prevent AA amyloi-
dosis. Interleukin-1 inhibitors were introduced since a
few years (anakinra and canakinumab), and it is still
unclear if they can cure secondary amyloidosis. However,
in 39% of cases they could allow a decrease of both pro-
teinuria and creatininemia. In addition, in our experience
and in the literature, anti IL1 treatments were able to
prevent amyloidosis-related fatality.
Conclusion
AA amyloidosis can occur in all types of CAPS. IL-1
inhibitors prevent the occurrence of AA amyloidosis
and should be started as soon as possible, even in FCAS
patients in case of subclinical inflammation.
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